Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection
Cynthia Portal‐Celhay, Eduardo Forleo‐Neto, Will Eagan, Bret J. Musser et autres
Importance: The monoclonal antibody combination of casirivimab and imdevimab reduced viral load, hospitalization, or death when administered as a 1200-mg or greater intravenous (IV) dose in a phase 3 COVID-19 outpatient study. Subcutaneous (SC) and/or lower IV doses should increase accessibility and/or …
us (code pays fourni par la source)
17 citations
JAMA Network Open